These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16625821)

  • 1. New targets in and potential treatments for cholesterol gallstone disease.
    Doggrell SA
    Curr Opin Investig Drugs; 2006 Apr; 7(4):344-8. PubMed ID: 16625821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.
    Moschetta A; Bookout AL; Mangelsdorf DJ
    Nat Med; 2004 Dec; 10(12):1352-8. PubMed ID: 15558057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
    Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
    Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between hepatic and biliary lipid metabolism and secretion in genetically gallstone-susceptible and gallstone-resistant mice.
    Xu G; Zhao L; Fuchs M
    Chin Med J (Engl); 2002 Sep; 115(9):1292-5. PubMed ID: 12411097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution of cholesterol gallstones in mice by the oral administration of a fatty acid bile acid conjugate.
    Gilat T; Leikin-Frenkel A; Goldiner I; Halpern Z; Konikoff FM
    Hepatology; 2002 Mar; 35(3):597-600. PubMed ID: 11870372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
    Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe prevents cholesterol gallstone formation in mice.
    Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
    Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesoid X receptor agonism -- a new approach to the treatment of cholesterol gallstone disease.
    Doggrell SA
    Expert Opin Investig Drugs; 2005 Apr; 14(4):535-8. PubMed ID: 15882126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FXR, a multipurpose nuclear receptor.
    Lee FY; Lee H; Hubbert ML; Edwards PA; Zhang Y
    Trends Biochem Sci; 2006 Oct; 31(10):572-80. PubMed ID: 16908160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice.
    Leikin-Frenkel A; Parini P; Konikoff FM; Benthin L; Leikin-Gobbi D; Goldiner I; Einarsson C; Gilat T
    Arch Biochem Biophys; 2008 Mar; 471(1):63-71. PubMed ID: 18167305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
    Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
    Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Innovations in the medical treatment of gallstones and fatty liver: FABACs (Fatty Acid Bile Acid Conjugates)].
    Keizman D; Goldiner I; Leikin-Frenkel A; Konikoff FM
    Harefuah; 2008 Apr; 147(4):344-9, 373, 372. PubMed ID: 18686819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expanding role of the bile acid receptor FXR in the small intestine.
    Cariou B; Staels B
    J Hepatol; 2006 Jun; 44(6):1213-5. PubMed ID: 16618512
    [No Abstract]   [Full Text] [Related]  

  • 18. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
    J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition protects against diet-induced gallstone formation through modulation of cholesterol and bile acid homeostasis.
    Lee EJ; Kim MH; Kim YR; Park JW; Park WJ
    Int J Mol Med; 2018 Mar; 41(3):1715-1723. PubMed ID: 29286073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
    Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
    Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.